VRTX Stock: Vertex Pharmaceuticals Incorporated Stock Price, Analysis & Insights
Get live vrtx stock price $436.34, comprehensive Vertex Pharmaceuticals Incorporated stock analysis, charts, news, and expert forecast. Real-time vrtx stock data and investment insights.
Loading chart...
Company Overview
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Company Information
- CEO
- Reshma Kewalramani FASN,
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6100
Contact Information
- Website
- https://www.vrtx.com
- Address
- 50 Northern Avenue
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Market leader with 112.0 billion market capitalization
✓ Strong presence in the Healthcare sector with established market position
✓ Growth-oriented company with premium valuation (P/E: 30.7)
✓ Lower volatility stock (Beta: 0.32) may provide portfolio stability
Business Model & Strategy
Vertex Pharmaceuticals Incorporated operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. As a mid-cap company, Vertex Pharmaceuticals Incorporated benefits from scale advantages, market presence, and established operations. Under the leadership of CEO Reshma Kewalramani FASN,, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Vertex Pharmaceuticals Incorporated competes in the Biotechnology within the broader Healthcare. With 112.0 billion in market capitalization, the company is positioned as a established player in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Select, Vertex Pharmaceuticals Incorporated provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Vertex Pharmaceuticals Incorporated should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Vertex Pharmaceuticals Incorporated shareholders
- ⚠Market volatility can significantly impact stock price, especially for mid-cap stocks
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Vertex Pharmaceuticals Incorporated
- ⚠Investors should consider how Vertex Pharmaceuticals Incorporated fits within their overall portfolio allocation
- ⚠Premium valuation (P/E: 30.7) requires strong growth to justify
Market Cap
111.97B
P/E Ratio
30.71
Beta
0.32
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 111.97B market capitalization
- Trading Volume: 528.68K shares traded today
- Price Range: 52-week range of $362.50 - $519.68
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated (VRTX) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 111.97B, the company represents a significant player in its market. The stock is currently trading at $436.34 with a negativedaily change of 0.19%.
The company's 6100 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 30.71, beta of 0.32, and 52-week price range from $362.50 to $519.68when evaluating investment opportunities.
Why Invest in Vertex Pharmaceuticals Incorporated?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under Reshma Kewalramani FASN,
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.